SS&C Technologies Holdings, Inc.

Good day and thank you for standing by. Welcome to SS&C Technologies' second quarter 2021 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. Please be advised that today's conference may be recorded. And if you require any further assistance, please press star 0. Thank you. I would now like to hand the conference over to your first speaker. Mr. Justine Stone, Head of Investor Relations. Please go ahead, ma'am.

Hi, everyone. Welcome and thank you for joining us for our second quarter 2021 earnings call. I'm Justine Stone, Investor Relations for S&C Technologies. With me today is Bill Stone, Chairman and Chief Executive Officer, Rahul Kanwar, President and Chief Operating Officer, and Patrick Pedanti, our Chief Financial Officer. Before we get started, we need to review the Safe Harbor Statement. Please note that various remarks we make today about future expectations, plans, and prospects, including the financial outlook we provide, constitute forward-looking statements for the purposes of the safe harbor provision under the Private Securities Allegation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the risk factor section of our most recent annual report on Form 10-K, which is on file with the SEC and can also be accessed on our website. These forward-looking statements represent our expectations only as of today, July 28, 2021. While the company may elect to update these forward-looking statements, it specifically disclaims any obligation to do so. During today's call, we will be referring to certain non-GAAP financial measures. The reconciliation of these non-GAAP financial measures to comparable GAAP financial measures is included in today's earnings release, which is located in the investor relations section of our website at www.ssctech.com. I will now turn the call over to Bill.

Thanks, Justine, and thanks, everyone, for joining. Our results for the first quarter are $1.261 billion in adjusted revenue, up 10.5%. and $1.24 in adjusted diluted earnings per share, up 19.2 percent. We surpassed $500 million in adjusted EBITDA in the quarter for the first time, coming in at $511 million. For the six months, our adjusted consolidated EBITDA was over $1 billion. Our adjusted consolidated EBITDA margin grew to 40.5 percent for the quarter. Our second quarter adjusted organic revenue was up 7.2%, the highest organic revenue growth quarter in several years. All of our businesses outperformed our expectations, and our alternatives, Interlink, SS&C Health, and DSP Financial Businesses drove the strong top-line growth. SS&T generated net cash from operating activities of $562 million for the six months ended June 30, 2021, even though we paid $144 million in cash taxes versus $35 million in 2020. We repurchased 2 million shares of common stock in Q2 2021 at an average price of $73.44 per share for $143.6 million. We paid down 183.1 million in debt for the first six months of 2021, and our leverage ratio continues to come down. As of Q2, at the end of Q2, our secured net leverage ratio was 2.09 times, and our total net leverage ratio had 3.1 times consolidated EBITDA. We remain fully committed to a shareholder-friendly capital allocation strategy. We're excited about last week's announcement that SS&C Health, along with our minority partners, Humana and Anthem, will form a joint venture to build the industry's most modern, sophisticated pharmacy benefit management platform. The newly formed entity, DomaniRx, will shape the future of PBM through a cloud-based, API-driven adjudication platform. This venture is the latest step in accelerating growth at SS&C Health. As we convene other participating members, we will have the ability to offer flexible tools, advanced analytics, and customizable programs to increase transparency. We expect the Domani Rx members to have an unrivaled pharmacy experience. Domani Rx will generate interest in our healthcare and pharmacy claims processing and analytics services now. The new technology will benefit both DemaniRx and our existing SS&C Health Business. We believe the healthcare industry's transaction processing, data analytics, and information delivery to be significantly hampered by outdated technology. The customer experience as well as the payer-provider experiences can be greatly enhanced with powerful, flexible technologies. The growth in life-saving pharmaceuticals and other prescription-based medicines There are over 4.5 billion prescriptions filled in the U.S. per year, as well as an aging population, makes this an ideal time to invest and deliver. Assistancee Health has years of experience running large-scale systems with the ability and expertise to handle volume and large customers. I'll now turn the call over to Rahul to discuss the quarter in more detail.